Clinical Trial Update: Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the addition of cabozantinib to cemiplimab for adolescents and adults with advanced adrenocortical carcinoma is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Carcinoma

Drugs mentioned

• Cabometyx (cabozantinib)
• Cemiplimab (cemiplimab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma | Phase 2 | Status: RECRUITING